You just read:

Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily LIXIANA®▼ (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation

News provided by

Daiichi Sankyo Company, Limited

30 Mar, 2017, 13:00 BST